| Item type |
文献 / Documents(1) |
| 公開日 |
2023-01-31 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1093/cid/ciac128 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1093/cid/ciac128 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events : A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
Daptomycin-related Musculoskeletal Adverse Events and Statin Use |
|
言語 |
en |
| 著者 |
中馬, 真幸
ナカモト, アキ
バンドウ, タカシ
新村, 貴博
コンドウ, ユタカ
濱野, 裕章
岡田, 直人
アサダ, ミズホ
座間味, 義人
武智, 研志
合田, 光寛
ミヤタ, コウジ
八木, 健太
ヨシオカ, トシヒコ
(井澤)石澤, 有紀
楊河, 宏章
タサキ, ヨシカズ
石澤, 啓介
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background. There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs.
Methods. We used a mixed approach that combines 2 methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population.
Results. In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83; 95% confidence interval [CI]: 1.43–10.26) but not DAP-related myopathy (OR: 1.72; 95% CI: .95–3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69; 95% CI: 4.31–7.51) and rhabdomyolysis (ROR: 5.77; 95% CI: 4.33–7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis.
Conclusion. The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
daptomycin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
statin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
musculoskeletal adverse event |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
meta-analysis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
disproportionality analysis |
| 書誌情報 |
en : Clinical Infectious Diseases
巻 75,
号 8,
p. 1416-1422,
発行日 2022-03-09
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
10584838 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
15376591 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10822963 |
| 出版者 |
|
|
出版者 |
Infectious Diseases Society of America |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| EID |
|
|
識別子 |
390814 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
cid_75_8_1416.pdf (1.82 MB)
.png)
